Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Results from the study, which focused on gynecological malignant tumors, were presented at the Society for Immunotherapy of ...

The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

She previously served as Chief Executive Officer at Harpoon Therapeutics until the company’s acquisition by Merck ... Product Development. Dr. Bruns previously served as the Senior Vice President and ...

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Jannie Oosthuizen, president, ...

In a report released yesterday, Evan Seigerman from BMO Capital maintained a Buy rating on Merck & Company (MRK – Research Report), ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

While crouching behind a boulder on the Bridger Mountains near Bozeman, Montana, Michel Louge watched in awe as the ...

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors.

Pharmaceuticals firm Merck reported a solid third quarter on Thursday, with revenue up 4% year-over-year to $16.7bn, driven by robust sales of its cancer drug Keytruda, although muted demand for the ...

While the Dow Jones Industrial Average has reached all-time highs recently, one of its newest members, Merck, traded briefly Thursday morning at a 52-week low.